Source facts
FDA issued an approval letter for CAMCEVI KIT on 2026-02-13. The source metadata identifies NDA 211488 as a supplement. Review the exact FDA letter for the approved conditions and labeling.
US FDA source recordAL · Approval Letter
CAMCEVI KIT — FDA Approval Letter (NDA 211488)
Issued to ACCORD. Application is approved as submitted.
Issued
February 13, 2026Application
NDA 505b1 • 211488
Product
CAMCEVI KIT
Company
ACCORD
Stage
Final Decision
Assyro regulatory brief
FreeWhat did FDA decide for CAMCEVI KIT?
Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
Key details in this letter
- 1FDA action: approval.
- 2Application: NDA 211488.
- 3Submission: supplement.
- 4Sponsor: ACCORD.
Suggested next step
Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.
Open the document workspaceFDA source document
Read the full FDA approval letter (PDF)
Loading document viewer…
Common questions about the CAMCEVI KIT approval letter
Is CAMCEVI KIT FDA approved?
This letter documents an FDA approval action: FDA approved NDA 211488 for CAMCEVI KIT, sponsored by ACCORD, on February 13, 2026. Product may be marketed. Verify current status and labeling in the source letter, since later FDA actions can change them.
What is NDA 211488?
NDA 211488 is the application under which FDA issued this approval letter for CAMCEVI KIT to ACCORD. The letter is dated February 13, 2026.
What happens after an FDA approval letter?
The sponsor may market the product in line with the approved labeling. Approval letters typically set post-approval obligations: submitting final content of labeling, meeting any postmarketing requirements or commitments listed in the letter, updating Orange Book patent information within 30 days for NDAs, and ongoing annual reporting under 21 CFR 314.81.